We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FINGOLIMOD DEVATIS (Devatis Pty Ltd)
Product name
FINGOLIMOD DEVATIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
103 (255 working days)
Active ingredients
fingolimod hydrochloride
Registration type
New generic medicine
Indication
FINGOLIMOD Devatis is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.